Open-label phase II/III study of nivolumab plus standard of care versus standard of care for first-line treatment of metastatic colorectal cancer: Checkmate-9X8 von Tabernero, Josep, Yoshino, Takayuki, Cohn, Allen Lee, Kochenderfer, Mark D., Holdridge, Regan C., Couture, Felix, Elez, Elena, Bendell, Johanna C., Zhou, Ming, Cullen, Dana, Lenz, Heinz-Josef

Volltext

Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer von Buist, Diana S. M, Abraham, Linn A, Barlow, William E, Krishnaraj, Arun, Holdridge, Regan C, Sickles, Edward A, Carney, Patricia A, Kerlikowske, Karla, Geller, Berta M

Volltext

Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phas... von Lenz, Heinz-Josef, Parikh, Aparna Raj, Spigel, David R., Cohn, Allen Lee, Yoshino, Takayuki, Kochenderfer, Mark D., Elez, Elena, Shao, Spencer H., Deming, Dustin A., Holdridge, Regan C., Larson, Timothy, Chen, Eric, Mahipal, Amit, Ucar, Antonio, Cullen, Dana, Baskin-Bey, Edwina S, Ledeine, Jean-Marie, Hammell, Amy, Tabernero, Josep

Volltext

The Novel Oral Typhoid Vaccine M01ZH09 Is Well Tolerated and Highly Immunogenic in 2 Vaccine Presentations von Kirkpatrick, Beth D., Tenney, Katherine M., Larsson, Catherine J., O’Neill, J. Patrick, Ventrone, Cassandra, Bentley, Matthew, Upton, Anthony, Hindle, Zoë, Fidler, Christine, Kutzko, Deborah, Holdridge, Regan, LaPointe, Casey, Hamlet, Sandra, Chatfield, Steven N.

Volltext